Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-26-058649
Filing Date
2026-05-11
Accepted
2026-05-11 16:08:30
Documents
88
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ganx-20260331x10q.htm   iXBRL 10-Q 1418439
2 EX-31.1 ganx-20260331xex31d1.htm EX-31.1 11150
3 EX-31.2 ganx-20260331xex31d2.htm EX-31.2 10316
4 EX-32.1 ganx-20260331xex32d1.htm EX-32.1 11668
  Complete submission text file 0001104659-26-058649.txt   7512695

Data Files

Seq Description Document Type Size
5 EX-101.SCH ganx-20260331.xsd EX-101.SCH 57023
6 EX-101.CAL ganx-20260331_cal.xml EX-101.CAL 55846
7 EX-101.DEF ganx-20260331_def.xml EX-101.DEF 196298
8 EX-101.LAB ganx-20260331_lab.xml EX-101.LAB 503502
9 EX-101.PRE ganx-20260331_pre.xml EX-101.PRE 376381
92 EXTRACTED XBRL INSTANCE DOCUMENT ganx-20260331x10q_htm.xml XML 1304157
Mailing Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814
Business Address 4800 HAMPDEN LANE SUITE 200 BETHESDA MD 20814 (301) 500-1556
Gain Therapeutics, Inc. (Filer) CIK: 0001819411 (see all company filings)

EIN.: 851726310 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40237 | Film No.: 26963231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)